Infection: Prostate biopsyinfection and prior fluoroquinolone exposure

Nature Reviews Urology

Volumn 8, Issue 11, 2011, Pages 592-594

  Liss, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; DIAGNOSTIC AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CANCER SCREENING; COMORBIDITY; DRUG EXPOSURE; DRUG UTILIZATION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; TRANSRECTAL ULTRASONOGRAPHY; ECHOGRAPHY; HIGH INTENSITY FOCUSED ULTRASOUND; MALE; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE DISEASE; REVIEW; URINARY TRACT INFECTION;

ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MALE; PROSTATE; PROSTATIC DISEASES; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL; URINARY TRACT INFECTIONS;

EID: 81055133432     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.153     Document Type: Article

References (10)

1. Hodge, K. K., McNeal, J. E. & Stamey, T. A. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J. Urol. 142, 66-70 (1989). (Pubitemid 19184005)
2. Naughton, C. K., Miller, D. C., Mager, D. E., Ornstein, D. K. & Catalona, W. J. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J. Urol. 164, 388-392 (2000). (Pubitemid 30481932)
3. Nam, R. K. et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J. Urol. 183, 963-968 (2010).
4. Liss, M. A. et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J. Urol. 185, 1283-1288 (2011).
5. Wolf, J. S., Jr et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J. Urol. 179, 1379-1390 (2008).
6. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61-71 (2011).
7. Mosharafa, A. A., Torky, M. H., El Said, W. M. & Meshref, A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 78, 511-514 (2011).
8. Akduman, B. et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 78, 250-255 (2011).
9. Horcajada, J. P. et al. High prevalence of extended-spectrum beta-lactamase-producing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol. Urology 74, 1195-1199 (2009).
10. Batura, D., Rao, G. G. & Nielsen, P. B. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJUI 106, 1017-1020 (2010).